Tumor immunity

Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma
Florian Hornsteiner, Janine Vierthaler, Helen Strandt, Antonia Resag, Zhe Fu, Markus Ausserhofer, Christoph H Tripp, Sophie Dieckmann, Markus Kanduth, Kathryn Farrand, Sarah Bregar, Niloofar Nemati, Natascha Hermann-Kleiter, Athanasios Seretis, Sudhir Morla, David Mullins, Francesca Finotello, Zlatko Trajanoski, Guido Wollmann, Franca Ronchese, Marc Schmitz, Ian F Hermans, Patrizia Stoitzner

Journal for ImmunoTherapy of Cancer Apr 2024, 12 (4) e008606; DOI: 10.1136/jitc-2023-008606
Nature of coexisting thyroid autoimmune disease determines success or failure of tumor immunity in thyroid cancer
Shahnawaz Imam, Pervaiz Dar, Rodis Paparodis, Khalil Almotah, Ahmed Al-Khudhair, Syed Abdul-Moiz Hasan, Nancy Salim, Juan Carlos Jaume

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 3; DOI: 10.1186/s40425-018-0483-y
Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma
Lisa H. Butterfield, Lazar Vujanovic, Patricia M. Santos, Deena M. Maurer, Andrea Gambotto, Joel Lohr, Chunlei Li, Jacob Waldman, Uma Chandran, Yan Lin, Huang Lin, Hussein A. Tawbi, Ahmad A. Tarhini, John M. Kirkwood

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 113; DOI: 10.1186/s40425-019-0552-x
29^th Annual meeting of the Society for Immunotherapy of Cancer (SITC)
Arthur A Hurwitz, Sylvia Lee, Susan Knox, Holbrook Kohrt, Gregory Verdeil, Emanuela Romano, Kim Margolin, Walter J Urba, Daniel E Speiser

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (1) 17; DOI: 10.1186/s40425-015-0062-4
The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells
Dominique N Lisiero, Horacio Soto, Richard G Everson, Linda M Liau, Robert M Prins

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 8; DOI: 10.1186/2051-1426-2-8
Cytokine responsiveness of CD8⁺ T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients
Richard G Everson, Richard M Jin, Xiaoyan Wang, Michael Safaee, Rudi Scharnweber, Dominique N Lisiero, Horacio Soto, Linda M Liau, Robert M Prins

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 10; DOI: 10.1186/2051-1426-2-10
The human CD40 agonistic antibody ADC-1013 generates immune mediated anti-tumor effects in syngeneic tumor models in hCD40 transgenic mice
Sara M Mangsbo, Niina Veitonmäki, Erika Gustfson, Karin Enell Smith, Christina Furebring, Per Norlén, Malin Lindstedt, Thomas H Tötterman, Peter Ellmark

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P251; DOI: 10.1186/2051-1426-2-S3-P251
Type II NKT cells differentially regulate CD4 T cell subsets
Faith C Robertson, Xiuju Lu, Masaki Terabe, Jay A Berzofsky

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P233; DOI: 10.1186/2051-1426-2-S3-P233
Siglec-7/-9 ligands shield tumor cells from NK cell attack
Camilla Jandus, Kayluz Frias Boligan, Obinna Chijioke, He Liu, Meike Dahlhaus, Thomas Démoulins, Christoph Schneider, Marc Wehrli, Robert E Hunger, Gabriela M Baerlocher, Hans-Uwe Simon, Pedro Romero, Christian Münz, Stephan von Gunten

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P157; DOI: 10.1186/2051-1426-1-S1-P157

Log in using your username and password

Main menu

Log in using your username and password

You are here

Tumor immunity